Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.
about
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysisSignificantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials
P2860
Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Trastuzumab, non-pegylated lip ...... HER-2 positive breast cancer.
@en
Trastuzumab, non-pegylated lip ...... HER-2 positive breast cancer.
@nl
type
label
Trastuzumab, non-pegylated lip ...... HER-2 positive breast cancer.
@en
Trastuzumab, non-pegylated lip ...... HER-2 positive breast cancer.
@nl
prefLabel
Trastuzumab, non-pegylated lip ...... HER-2 positive breast cancer.
@en
Trastuzumab, non-pegylated lip ...... HER-2 positive breast cancer.
@nl
P2093
P2860
P1476
Trastuzumab, non-pegylated lip ...... HER-2 positive breast cancer.
@en
P2093
María José Agustín-Ferrández
María Reyes Abad-Sazatornil
Moisés Uriarte-Pinto
Oihana Pascual-Martínez
Vicente Gimeno-Ballester
Ángel Escolano-Pueyo
P2860
P2888
P304
P356
10.1007/S11096-016-0278-5
P577
2016-03-07T00:00:00Z